Question special
Lead Moderator

I want to thank everyone for the excellent discussion so far. Today, I wanted to ask a specific question about Figure 1B and D. In these charts, the anti-factor Xa activity was evaluated over time in the rivaroxaban study. In each of these charts, there seems to be a rebound increase in anti-factor Xa activity relative to placebo after the curves cross each other. This phenomenon is also seen in Figure 3B and D, which plot the amount of unbound rivaroxaban over time. Of note, this is not seen in the apixaban group, and does not carry over to the thrombin curves. Why would we see this effect, and particularly, why in rivaroxaban? Do you think this finding may be clinically important?